<DOC>
	<DOCNO>NCT00870285</DOCNO>
	<brief_summary>Ustekinumab , IL-12/23 antibody approve E.C . U.S.A. treatment moderate severe psoriasis . The aim study determine randomize half-side comparison whether additional narrowband UVB-311nm phototherapy accelerate improve clearance skin lesion Ustekinumab-treated patient .</brief_summary>
	<brief_title>Ustekinumab Plus UVB-311nm Psoriasis</brief_title>
	<detailed_description>Patients moderate severe psoriasis receive standard treatment Ustekinumab ( 45 mg week 0 , 4 , every 12 week ) expose UVB-311nm phototherapy randomize body half ( left right ; head exempt ) 3 x per week six week and/or complete response ( define reduction PASI &lt; 3 ) . PASI score , patient visual analogue score ( VAS ) therapeutic response , patient VAS severity skin lesion assess weekly ; follow-up visit month 3 , 6 , 12 . Paired Wilcoxon test difference PASI patient VAS score do ; Fischer exact test apply determine difference complete remission , PASI reduction &gt; 90 % , &gt; 75 % and/or 50 % body sit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Age &gt; 18 year Psoriasis patient receive treatment Ustekinumab Age 18 year Pregnancy lactation History malignant melanoma History invasive squamous cell carcinoma skin Dysplastic melanocytic nevus syndrome Antinuclear antibody ( dsDNA , Ro/SSA , La/SSB ) Autoimmune disorder Lupus erythematosus Dermatomyositis Photosensitive diseases porphyria , chronic actinic dermatitis , Xeroderma pigmentosum , basal cell nevus syndrome , others General poor health status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Biologic</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>UVB-311nm narrowband</keyword>
	<keyword>phototherapy</keyword>
	<keyword>half-side comparison</keyword>
</DOC>